Den europeiske union -
norsk -
EMA (European Medicines Agency)
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - immunsuppressive - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
Norge -
norsk -
Statens legemiddelverk
venclyxto 10 mg
abacus medicine a/s - venetoklaks - tablett, filmdrasjert - 10 mg
Norge -
norsk -
Statens legemiddelverk
venclyxto 50 mg
abacus medicine a/s - venetoklaks - tablett, filmdrasjert - 50 mg
Norge -
norsk -
Statens legemiddelverk
venclyxto 100 mg
abacus medicine a/s - venetoklaks - tablett, filmdrasjert - 100 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - cytostatika - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
